Samir H. Barghout, et al., Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC pa‐ tients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study, Lung Cancer, 2024....
Cancer Center,Sun Yat-sen University癌症Westcott PM, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013; 32 :63–70.P. M. K. Westcott and M. D. To, "The genetics and biology of KRAS in lung cancer," Chinese Journal of Cancer, vol. 32, no. 2, pp....
[3]Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer.Nature. 2014;507(7491):190-194. doi:10.1038/nature12930 [4] Juul NH, Yoon JK, Martinez MC, et al. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming ...
4、AST可塑性特征和KRT6A富集预测adagasib反应较差 项目研究组2024年2月22日在《Cancer cell》上发表了题目为“Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer”的研究成果, 其通讯作者为Hongbin Ji等人。 KRAS,这个在肺腺癌(ADC)里频繁突变的基因,特别是在密码子12...
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥ 50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM)[J]. Journal of Thoracic Oncology, 2023....
满足上面的基本条件，可联系癌度报名，参加这款新药的临床试验。一旦筛选入组患者的检查和药物费用全免。欢迎大家关注癌度，了解最新的肿瘤诊疗信息！参考文献：Rafael Rosell, et al., KRAS G12C-mutant driven non-small cell lung cancer (NSCLC), Critical Reviews in Oncology / Hematology, (2023).
2024年2月22日，中国科学院分子细胞科学卓越创新中心季红斌课题组联合纽约大学医学院Kwok-Kin Wong团队，哈佛医学院丹娜法伯癌症研究所Andrew J. Aguirre团队以及清华大学张奇伟团队在CancerCell上发表文章Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1-mutant lung cancer。该研究发现肺腺鳞癌...
[4] Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. doi:10.1200/JCO.2000.18.10.2095 [5] ...
[1]Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2204619. [2]Negrao MV, Spira AI, Heist RS, et al. Intracranial E...
1. EusebioManchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51. 2. Hidenori Kitai, et al. Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mu...